Switching from Biosimilar to Biosimilar Adalimumab, Including Multiple Switching, in Crohn’s Disease: A Prospective Study

Switching from Biosimilar to Biosimilar Adalimumab, Including Multiple Switching, in Crohn’s Disease: A Prospective Study

No data are available regarding the safety and effectiveness of the biosimilar-to-biosimilar switch of adalimumab in any disease, and in particular in Crohn’s disease (CD). The aim of our study was to provide real world data on switching from biosimilar adalimumab to another biosimilar, including mu...

Full description

Bibliographic Details
Main Authors: Davide Giuseppe Ribaldone, Elisa Tribocco, Chiara Rosso, Angelo Armandi, Marta Vernero, Elisabetta Bugianesi, Marco Astegiano, Giorgio Maria Saracco, Gian Paolo Caviglia
Format: Article
Language:English
Published: MDPI AG 2021-07-01
Series:Journal of Clinical Medicine
Subjects:
originator
Amgevita
Amjevita
Imraldi
Online Access:https://www.mdpi.com/2077-0383/10/15/3387

Internet

https://www.mdpi.com/2077-0383/10/15/3387

Similar Items